The GARD® technology.
The key elements of the platform
SenzaGen’s GARD (Genomic Allergen Rapid Detection™) platform comprises a series of tests that are all designed according to the same principle, which is comprised of four key elements: a biological cell system, a training dataset, a genomic biomarker signature and a prediction model.
Holistic approach – improved accuracy and human relevance
The GARD assays were developed with a holistic view, utilizing genomics and machine-learning technology to reflect the complex processes underlying an immune response, e.g. skin sensitization.
Traditional in vitro tests investigate only a few biomarkers and provide limited information to give reliable results. Animal tests provide much more information which, however, are not always human-relevant. By using a genomics-based approach with machine-learning technology, GARD combines the simplicity of in vitro methods and the biological intricacy of in vivo models.
This holistic approach contributes to improved accuracy and human relevance. For example, the predictive accuracy of animal tests for skin sensitization assessment is estimated from 70% to 75%; the traditional in vitro tests are ranging from 75% to 80%, while GARDskin has a predictive accuracy of over 90%.